logoAiPathly

BioAge Labs

B

Leadership Team

BioAge Labs, a clinical-stage biopharmaceutical company, boasts a diverse and experienced leadership team driving its mission to develop therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Key members include:

CEO and Co-Founder

  • Kristen Fortney, PhD: Serving as CEO, President, and Treasurer since April 2015. Her annual compensation is approximately $1.38 million, with a 3.38% direct ownership of company shares.

Co-Founder

  • Eric Morgen: Leads human cohort partnerships and computational efforts for drug target discovery. His background spans artificial intelligence, medicine, and computational biology.

Chief Medical Officer & Executive VP of Research

  • Paul Rubin: Heads clinical development of BioAge's aging-targeted therapies. He brings extensive experience from pharmaceutical and biotech industries.

Chief Financial Officer

  • Dov Goldstein: Brings over 20 years of strategic financial and operational experience in healthcare, having held leadership roles at various biotech companies.

Other Key Positions

  • Chief Business Officer & Therapeutic Area Head of Brain Aging
  • Senior Vice President of Regulatory Affairs
  • Senior Vice President of Translational Aging Biology
  • Chief Strategy Officer

Board of Directors

  • Jean-Pierre Garnier, PhD: Recently appointed Chair, former CEO of GlaxoSmithKline
  • James Healy, MD, PhD: Former Chair, continuing board member and managing partner of Sofinnova Investments The leadership team combines seasoned executives and visionary co-founders, each contributing significant expertise to advance BioAge Labs' innovative approach to treating age-related diseases.

Core Technology

BioAge Labs leverages a data-driven approach to understand and target the biology of human aging, focusing on cardiometabolic and age-related diseases. Their core technology encompasses several key components:

Data Collection and Analysis

BioAge Labs utilizes extensive longitudinal human longevity data, primarily from blood samples, including:

  • Proteomics: Analyzing 5,000 proteins
  • Metabolomics: Examining several thousand metabolites
  • Gene expression: Analyzing tens of thousands of gene expressions using RNA-Seq

AI and Machine Learning

Advanced AI and ML algorithms are employed to analyze the vast dataset, identifying key molecular factors that change with age and predict future health outcomes. This approach distinguishes between healthy and unhealthy aging profiles.

Longitudinal Omics and Functional Assessments

The platform integrates longitudinal omics data with serial functional assessments, modeling aging-related physical, cognitive, and functional decline. This method captures healthspan trajectories starting from healthy individuals.

Discovery and Development

BioAge's platform identifies translational drug targets by analyzing the complex interplay of biological pathways related to metabolic aging. An unbiased approach is used to identify targets, which are then validated through an in-house translational aging core in naturally aged mice.

Collaboration and Integration

The company collaborates with industry leaders like Novartis, combining their human longevity datasets with external expertise to discover and validate new therapeutic drug targets.

Bespoke Data Science Ecosystem

BioAge has developed a custom data science ecosystem utilizing AI and ML to generate insights from human aging cohorts, crucial for identifying and validating potential therapeutic targets. By integrating these elements, BioAge Labs aims to develop therapies targeting fundamental biological pathways of human aging, with the goal of improving health outcomes and increasing healthspan.

Industry Peers

BioAge Labs operates within the biotechnology industry, focusing on aging and age-related metabolic diseases. Key industry peers and competitors include:

UNITY Biotechnology

A significant competitor developing therapeutics targeting diseases of aging, listed on NASDAQ under the ticker symbol UBX.

FibroGen

Known for developing innovative therapeutics in areas such as anemia and fibrosis, aligning with BioAge Labs' focus on metabolic and aging-related diseases.

Amgen

A major biotechnology company with a robust pipeline of therapeutics targeting metabolic diseases, including obesity and related conditions.

Novo Nordisk

A prominent player in the biotechnology sector, with a strong focus on diabetes and obesity treatments, presenting significant competition in the metabolic diseases space.

Regeneron Pharmaceuticals

Known for its innovative approach to drug development, particularly in metabolic disorders, posing a challenge to BioAge Labs with cutting-edge technologies and therapies.

Vertex Pharmaceuticals

While primarily focused on rare diseases and genetic disorders, Vertex presents competition in the broader biotech space due to innovative approaches and significant resources.

Other Competitors

Additional companies in the broader biotechnology and healthcare space that may overlap with BioAge Labs' research areas include:

  • DiaCarta
  • Mission Bio
  • Quadrants Scientific These competitors highlight the dynamic and competitive nature of the aging and metabolic diseases biotechnology sector, driving innovation and advancements in therapeutic development.

More Companies

B

BlackRock

BlackRock, Inc. is the world's largest asset management company, founded in 1988. As of December 31, 2023, it manages approximately $11.5 trillion in assets, with a global presence spanning 70 offices in 30 countries and serving clients in 100 countries. Key aspects of BlackRock include: 1. Products and Services: - Open-end and closed-end mutual funds - Exchange-traded funds (ETFs), notably through iShares - Fixed income, equity, alternatives, and multi-asset class mandates - Cash management and advisory services - Risk management solutions via Aladdin software and BlackRock Solutions 2. Client Base: BlackRock serves a diverse range of clients, including pension plans, governments, insurance companies, official institutions, endowments, foundations, charities, corporations, banks, sovereign wealth funds, and individual investors. Approximately two-thirds of managed assets are related to retirement. 3. Corporate Structure: BlackRock is a publicly traded company listed on the New York Stock Exchange (NYSE: BLK) since 1999. It operates independently, with ownership distributed among institutional and individual investors, including BlackRock employees. 4. ESG Focus and Criticisms: The company positions itself as a leader in environmental, social, and governance (ESG) considerations. However, it has faced criticism for investments in fossil fuels and arms industries, as well as its connections to the Federal Reserve and Chinese government-linked entities. 5. Technology and Risk Management: BlackRock is renowned for its Aladdin software, a comprehensive enterprise investment system used by major financial institutions for portfolio management and risk analysis. 6. Community Impact: The company emphasizes its role in community growth through investments in public projects such as transportation infrastructure and schools. In summary, BlackRock is a global leader in asset and risk management, known for its extensive product offerings, technological innovation, and commitment to ESG practices, while navigating various criticisms related to its investment strategies and influence.

S

SandboxAQ

SandboxAQ is a cutting-edge technology company founded in 2021, focusing on leveraging the combined power of artificial intelligence (AI) and quantum technologies to address significant challenges across various industries. ### Key Areas of Focus 1. **Quantum Cybersecurity**: - SandboxAQ specializes in quantum cybersecurity, particularly in migrating enterprises to post-quantum cryptography (PQC) to protect against future quantum computer attacks. - They utilize an AI Discovery Engine to identify and manage encryption across organizations, including banks, pharmaceutical companies, government agencies, and telecom companies. - The company has acquired Cryptosense and invested in quantum security companies like eVolutionQ and Qunnect. 2. **Computational Chemistry and Drug Discovery**: - SandboxAQ employs AI-driven computational drug discovery using quantum-inspired computations and tensor network algorithms on high-performance GPU clusters. - This approach allows for the generation and simulation of molecular permutations without requiring a large library of candidates. - They collaborate with biopharma companies on drugs for Alzheimer's, Parkinson's Disease, and oncology. 3. **Quantum Sensing**: - The company develops ultrasensitive quantum magnetic sensors with applications in navigation, particularly in GPS-denied environments, and medical diagnostics. - These sensors can be used for heart diagnostics as an alternative to EKGs. ### Business and Operations - **Funding**: SandboxAQ has raised $500.23 million from investors including T. Rowe Price, TIME Ventures, and Breyer Capital. - **Growth and Team**: The company has grown from 55 to over 129 employees across more than 8 countries, with 65% holding PhDs and 20% being engineers. - **Public Sector**: SandboxAQ works closely with government agencies to deploy AI and quantum technologies for various applications, including protecting sensitive data and accelerating materials discovery. ### Technology and Infrastructure - **Hybrid Approach**: SandboxAQ combines classical computing architecture with AI and quantum technologies, designed to run on current infrastructure with the ability to integrate with future quantum computers. - **Strategic Investments**: The company has a Strategic Investment Program aimed at growing through acquisitions and investments in the quantum and AI ecosystem. In summary, SandboxAQ leads in integrating AI and quantum technologies, addressing critical challenges in cybersecurity, drug discovery, and sensing, while supporting significant public sector initiatives.

B

BitGo

H

Hippocratic AI

Hippocratic AI is a pioneering company in the field of generative AI for healthcare applications. Their mission is to improve healthcare accessibility and outcomes through safety-focused large language models (LLMs). ### Mission and Products - Dedicated to building patient-centered, non-diagnostic AI tools - Core product: Polaris, a constellation architecture of LLMs - Primary AI agent leads conversations, supported by specialist agents ### Applications - Patient Engagement: Personalized messaging for medication schedules and follow-up care - Administrative Support: Assistance with licensure exams and compliance certifications - Clinical Support: Performing well on medical certification exams ### Safety and Compliance - Pre-trained on trusted, evidence-based healthcare content - Rigorous testing and validation process - Extensive safety assessments by clinicians ### AI Agent App Store - Allows clinicians to design and monetize AI agents - Rapid creation process with safety testing and certification ### Business Model and Funding - Monetization through subscriptions or licensing fees - Primary customers: hospitals, telehealth providers, and healthcare services - Total funding: $278 million from prominent investors ### Leadership - Co-founded by Munjal Shah and a diverse team of healthcare and AI professionals - Expertise from institutions like El Camino Health, Johns Hopkins, Stanford, Microsoft, Google, and NVIDIA